A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary

Péter Lakatos, István Takács, István Marton, Emese Tóth, Cina Zoltan, Zsolt Lang, Emi Psachoulia, Michele Intorcia

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

This study assessed persistence and compliance with anti-osteoporosis therapies, and associations between compliance and clinical outcomes (fracture, fracture-related hospitalization and death), in Hungarian women with postmenopausal osteoporosis. The study used the Hungarian National Health Insurance Fund Administration database and included women with PMO aged at least 50 years, for whom a prescription for anti-osteoporosis medication had been filled between 1 January 2004 and 31 December 2013 (index event). Persistence (prescription refilled within 8 weeks of the end of the previous supply) was evaluated over 2 years; good compliance (medication possession ratio ≥ 80 %) was evaluated at 1 year. Associations between compliance and clinical outcomes (data collected for up to 6 years) were assessed with adjustment for baseline covariates. A total of 296,300 women met the inclusion criteria (524,798 index events). Persistence and compliance were higher for less frequent and parenteral therapies (1- and 2-year persistence: half-yearly [parenteral] vs. daily/weekly/monthly [oral and parenteral], 81 and 38 % vs. 21–34 and 10–18 %, respectively; parenteral vs. oral, 75 and 36 % vs. 32 and 16 %; good compliance: half-yearly vs. daily/weekly/monthly, 70 vs. 24–39 %; parenteral vs. oral 78 vs. 36 %). Good compliance significantly reduced the risks of fracture, fracture-related hospitalization and death (relative risk vs. non-compliance [95 % confidence interval]: 0.77 [0.70–0.84], 0.72 [0.62–0.85] and 0.57 [0.51–0.64], respectively; P 

Original languageEnglish
Pages (from-to)215-225
Number of pages11
JournalCalcified Tissue International
Volume98
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Hungary
Osteoporosis
Compliance
Longitudinal Studies
Databases
Prescriptions
Hospitalization
Postmenopausal Osteoporosis
Medication Adherence
National Health Programs
Therapeutics
Confidence Intervals

Keywords

  • Compliance
  • Death
  • Fracture
  • Hospitalization
  • Osteoporosis
  • Persistence

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary. / Lakatos, Péter; Takács, István; Marton, István; Tóth, Emese; Zoltan, Cina; Lang, Zsolt; Psachoulia, Emi; Intorcia, Michele.

In: Calcified Tissue International, Vol. 98, No. 3, 01.03.2016, p. 215-225.

Research output: Contribution to journalArticle

Lakatos, Péter ; Takács, István ; Marton, István ; Tóth, Emese ; Zoltan, Cina ; Lang, Zsolt ; Psachoulia, Emi ; Intorcia, Michele. / A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary. In: Calcified Tissue International. 2016 ; Vol. 98, No. 3. pp. 215-225.
@article{69f164d2a3ba4b42b43874c0547c41af,
title = "A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary",
abstract = "This study assessed persistence and compliance with anti-osteoporosis therapies, and associations between compliance and clinical outcomes (fracture, fracture-related hospitalization and death), in Hungarian women with postmenopausal osteoporosis. The study used the Hungarian National Health Insurance Fund Administration database and included women with PMO aged at least 50 years, for whom a prescription for anti-osteoporosis medication had been filled between 1 January 2004 and 31 December 2013 (index event). Persistence (prescription refilled within 8 weeks of the end of the previous supply) was evaluated over 2 years; good compliance (medication possession ratio ≥ 80 {\%}) was evaluated at 1 year. Associations between compliance and clinical outcomes (data collected for up to 6 years) were assessed with adjustment for baseline covariates. A total of 296,300 women met the inclusion criteria (524,798 index events). Persistence and compliance were higher for less frequent and parenteral therapies (1- and 2-year persistence: half-yearly [parenteral] vs. daily/weekly/monthly [oral and parenteral], 81 and 38 {\%} vs. 21–34 and 10–18 {\%}, respectively; parenteral vs. oral, 75 and 36 {\%} vs. 32 and 16 {\%}; good compliance: half-yearly vs. daily/weekly/monthly, 70 vs. 24–39 {\%}; parenteral vs. oral 78 vs. 36 {\%}). Good compliance significantly reduced the risks of fracture, fracture-related hospitalization and death (relative risk vs. non-compliance [95 {\%} confidence interval]: 0.77 [0.70–0.84], 0.72 [0.62–0.85] and 0.57 [0.51–0.64], respectively; P ",
keywords = "Compliance, Death, Fracture, Hospitalization, Osteoporosis, Persistence",
author = "P{\'e}ter Lakatos and Istv{\'a}n Tak{\'a}cs and Istv{\'a}n Marton and Emese T{\'o}th and Cina Zoltan and Zsolt Lang and Emi Psachoulia and Michele Intorcia",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00223-015-0082-6",
language = "English",
volume = "98",
pages = "215--225",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary

AU - Lakatos, Péter

AU - Takács, István

AU - Marton, István

AU - Tóth, Emese

AU - Zoltan, Cina

AU - Lang, Zsolt

AU - Psachoulia, Emi

AU - Intorcia, Michele

PY - 2016/3/1

Y1 - 2016/3/1

N2 - This study assessed persistence and compliance with anti-osteoporosis therapies, and associations between compliance and clinical outcomes (fracture, fracture-related hospitalization and death), in Hungarian women with postmenopausal osteoporosis. The study used the Hungarian National Health Insurance Fund Administration database and included women with PMO aged at least 50 years, for whom a prescription for anti-osteoporosis medication had been filled between 1 January 2004 and 31 December 2013 (index event). Persistence (prescription refilled within 8 weeks of the end of the previous supply) was evaluated over 2 years; good compliance (medication possession ratio ≥ 80 %) was evaluated at 1 year. Associations between compliance and clinical outcomes (data collected for up to 6 years) were assessed with adjustment for baseline covariates. A total of 296,300 women met the inclusion criteria (524,798 index events). Persistence and compliance were higher for less frequent and parenteral therapies (1- and 2-year persistence: half-yearly [parenteral] vs. daily/weekly/monthly [oral and parenteral], 81 and 38 % vs. 21–34 and 10–18 %, respectively; parenteral vs. oral, 75 and 36 % vs. 32 and 16 %; good compliance: half-yearly vs. daily/weekly/monthly, 70 vs. 24–39 %; parenteral vs. oral 78 vs. 36 %). Good compliance significantly reduced the risks of fracture, fracture-related hospitalization and death (relative risk vs. non-compliance [95 % confidence interval]: 0.77 [0.70–0.84], 0.72 [0.62–0.85] and 0.57 [0.51–0.64], respectively; P 

AB - This study assessed persistence and compliance with anti-osteoporosis therapies, and associations between compliance and clinical outcomes (fracture, fracture-related hospitalization and death), in Hungarian women with postmenopausal osteoporosis. The study used the Hungarian National Health Insurance Fund Administration database and included women with PMO aged at least 50 years, for whom a prescription for anti-osteoporosis medication had been filled between 1 January 2004 and 31 December 2013 (index event). Persistence (prescription refilled within 8 weeks of the end of the previous supply) was evaluated over 2 years; good compliance (medication possession ratio ≥ 80 %) was evaluated at 1 year. Associations between compliance and clinical outcomes (data collected for up to 6 years) were assessed with adjustment for baseline covariates. A total of 296,300 women met the inclusion criteria (524,798 index events). Persistence and compliance were higher for less frequent and parenteral therapies (1- and 2-year persistence: half-yearly [parenteral] vs. daily/weekly/monthly [oral and parenteral], 81 and 38 % vs. 21–34 and 10–18 %, respectively; parenteral vs. oral, 75 and 36 % vs. 32 and 16 %; good compliance: half-yearly vs. daily/weekly/monthly, 70 vs. 24–39 %; parenteral vs. oral 78 vs. 36 %). Good compliance significantly reduced the risks of fracture, fracture-related hospitalization and death (relative risk vs. non-compliance [95 % confidence interval]: 0.77 [0.70–0.84], 0.72 [0.62–0.85] and 0.57 [0.51–0.64], respectively; P 

KW - Compliance

KW - Death

KW - Fracture

KW - Hospitalization

KW - Osteoporosis

KW - Persistence

UR - http://www.scopus.com/inward/record.url?scp=84957844734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957844734&partnerID=8YFLogxK

U2 - 10.1007/s00223-015-0082-6

DO - 10.1007/s00223-015-0082-6

M3 - Article

VL - 98

SP - 215

EP - 225

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 3

ER -